QIAGEN’s QuantiFERON-TB ® Gold Plus Wins UN Migration Agency’s Tender
International Organization for Migration selects most advanced test for latent TB infection
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON-TB® Gold Plus
(QFT-Plus), the gold standard in accurate, cost-effective testing for latent tuberculosis (TB) infection, has been
adopted by the International Organization for Migration (IOM) for use in screening migrants for the infection.
As the United Nations migration agency, IOM coordinates comprehensive healthcare for about 20 million migrants, refugees and
asylum-seekers around the world. The IOM tender covers use of QFT-Plus in 16 countries in Africa, Asia and the Middle East facing
public health challenges from TB as part of their 5-year Global Plan to End TB 2016-2020.
QIAGEN is collaborating with governments and international institutions, non-governmental organizations and commercial partners
in fighting the global epidemic of tuberculosis. Experts around the world are increasingly recognizing that accurate,
laboratory-based screening for latent TB infections – which can progress to active, contagious tuberculosis – is essential to
effective TB control. So far in 2018, the World Health Organization (WHO) and U.S. Centers for Disease Control (CDC) all have
endorsed latent TB screening with interferon-gamma release assays (IGRAs) such as QIAGEN’s fourth-generation QFT-Plus and
third-generation QuantiFERON-TB® Gold (QFT). Furthermore, the International Panel Physicians Association (IPPA) has
endorsed QFT-Plus specifically.
Please find the full press release here
###
Investor Relations
John Gilardi
+49 2103 29 11711
or
Dr. Sarah Fakih
+49 2103 29 11457
e-mail: ir@QIAGEN.com
or
Public Relations
Dr. Thomas Theuringer
+49 2103 29 11826
or
Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180730005548/en/